Dyne Therapeutics Balance Sheet
NASDAQ: DYNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Dyne Therapeutics financial position
At the end of fiscal 2025, Dyne Therapeutics reported total assets of $1.19 billion, up 71.7% from a year earlier against total liabilities of $214.8 million. Shareholders' equity stood at $972.1 million, or 81.9% of assets. The company held $893.4 million in cash and equivalents against $148.9 million of debt, a net cash position of $744.4 million.
The current ratio (current assets divided by current liabilities) was 22.25, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.15.
Summary generated from market data by MetaCap's automated system. Methodology
Dyne Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 893.37M | 435.45M | 121.63M | 172.15M | 200.82M | 300.85M | 14.63M |
| Short-Term Investments | 217.19M | 206.82M | 1.47M | 83.86M | 175.75M | 44.46M | 0 |
| Total Current Assets | 1.13B | 659.28M | 129.38M | 265.59M | 382.39M | 349.09M | 14.76M |
| Property, Plant & Equipment | 24.03M | 5.40M | 4.78M | 5.95M | 4.68M | 1.95M | 1.49M |
| Total Assets | 1.19B | 691.23M | 165.08M | 306.32M | 425.66M | 353.33M | 16.44M |
| Accounts Payable | 8.08M | 6.56M | 22.94M | 5.26M | 4.03M | 3.44M | 1.26M |
| Total Current Liabilities | 50.63M | 42.26M | 51.09M | 28.09M | 28.72M | 10.97M | 2.36M |
| Long-Term Debt | 148.92M | 0 | — | — | — | — | — |
| Total Liabilities | 214.83M | 61.40M | 73.79M | 53.96M | 57.47M | 10.97M | 2.40M |
| Shareholders' Equity | 972.13M | 629.84M | 91.29M | 252.36M | 368.20M | 342.37M | 14.04M |
| Retained Earnings | -1.40B | -949.93M | -632.51M | -396.57M | -228.47M | -79.18M | -19.75M |
| Total Debt | 148.92M | 0 | — | — | — | — | — |
| Net Cash (Debt) | 961.64M | 642.27M | 123.10M | 256.01M | 376.57M | 345.31M | 14.63M |
| Shares Outstanding | 164.95M | 102.32M | 61.47M | 55.64M | 51.57M | 45.08M | 2.59M |
This table shows 7 annual periods of Dyne Therapeutics's balance sheet, from FY 2025 back to FY 2019, across 14 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow DYN's reporting calendar. What is a balance sheet?